Similar results were obtained by Yakimchuk et al. [155] in a mouse model of T-cell lymphoma, using both wild-type and ERβ−/− animals, where ERβ agonists were able to prevent angiogenesis and tumor spread. This evidence concerns the gene ESR2 and T-cell non-Hodgkin lymphoma.